Serotype 3 Experimental Human Pneumococcal Challenge (EHPC) study protocol: dose ranging and reproducibility in a healthy volunteer population (challenge 3)
Introduction Since the introduction of pneumococcal conjugate vaccines, pneumococcal disease rates have declined for many vaccine-type serotypes. However, serotype 3 (SPN3) continues to cause significant disease and is identified in colonisation epidemiological studies as one of the top circulating...
Main Authors: | Maia Lesosky, Konstantinos Liatsikos, Stephen B Gordon, Kelly Davies, Phoebe Hazenberg, Angela Hyder-Wright, Ryan E Robinson, Britta Urban, Elena Mitsi, Carla Solorzano, Daniela M Ferreira, Madlen Farrar, Ashleigh Howard, Andrea M Collins, Jaye Brunning, Hannah Fleet, Amy Bettam, Tinashe Kenny-Nyazika, Dima El Safadi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/1/e075948.full |
Similar Items
-
Comprehensive review of safety in Experimental Human Pneumococcal Challenge.
by: Ryan E Robinson, et al.
Published: (2023-01-01) -
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination
by: Elena Mitsi, et al.
Published: (2023-10-01) -
Technological Challenges and Sustainable Development
by: Alina Mihaela Dima
Published: (2023-11-01) -
3. Contemporary Challenges in Arts Education the Challenges of Here and Now
by: Bilic Laura
Published: (2022-04-01) -
ASYMMETRIC-SYNTHESIS - MEETING THE CHALLENGE
by: Davies, S, et al.
Published: (1989)